Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan Dose Comparison in MBF Conditioning for AML/MDS
NCT06829472Phase 3Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Dec 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of melphalan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Shanghai Jiao Tong University School of Medicine. Started Dec 2023; status: recruiting.
02
Drugs
melphalan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06829472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06829472.